SCHEMBL3492211

SCHEMBL3492211

Cc1c(C(=O)O)sc2nc(Cc3cccc(Cl)c3)[nH]c(=O)c12.[NaH]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.67
ALDH1A1 P00352 9/20 0.59
KMT2A Q03164 7/20 0.59
KDM4E B2RXH2 2/20 0.59
MAPT P10636 5/20 0.55
POLB P06746 5/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 5/20 0.51
MEN1 O00255 5/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
PLEC Q15149 1/20 0.51
USP2 O75604 1/20 0.50
THRB P10828 1/20 0.50
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
HPGD P15428 1/20 0.49
APEX1 P27695 1/20 0.49
RECQL P46063 1/20 0.49
MCL1 Q07820 1/20 0.49
PIP4K2A P48426 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492352 0.99 PDE5A (0.69) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL37776 0.89 PDE5A (0.61) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL3492213 0.88 PDE5A (0.60) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL3494144 0.88 MAPT (0.63) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL3491253 0.88 MAPT (0.57) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL3493794 0.87 KMT2A (0.59) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL3491916 0.87 ALDH1A1 (0.61) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL4518642 0.87 PIP4K2A (0.66) PDE5AALDH1A1KMT2AKDM4EMAPT
SCHEMBL13341339 0.86 ALDH1A1 (0.75) ALDH1A1KMT2AKDM4EMAPTPOLB
SCHEMBL3493088 0.86 POLB (0.64) PDE5AALDH1A1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD PDE5A 14/4885ALDH1A1 762/4885KMT2A 2820/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 PDE5A 25/4885ALDH1A1 2303/4885KMT2A 2650/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 PDE5A 25/4885ALDH1A1 2303/4885KMT2A 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.